Royalty Pharma
RPRXRoyalty Pharma is the leading buyer of biopharmaceutical royalties and a primary funder of innovation across the life sciences industry.
Earnings
Next report
Nov 4, 2026 (in 2 months)Financials
Q2 2026Valuation & ratios
Competitors
By market cap
By revenue growth
Profile
Royalty Pharma is the leading buyer of biopharmaceutical royalties and a primary funder of innovation across the life sciences industry. The company acquires interests in the top-line sales of approved and development-stage therapies, providing non-dilutive capital to academic institutions, non-profits, and biotechnology companies. Its business model offers investors diversified exposure to high-growth blockbuster drugs while mitigating the operational risks and costs associated with traditional drug development and commercialization.
The company is the largest player in the biopharmaceutical royalty market, holding a significant market share of large-scale transactions compared to its nearest competitors.
FAQ
- What is Royalty Pharma's market cap?
- Royalty Pharma (RPRX) has a market capitalization of $27.5B and trades on NASDAQ.
- What is Royalty Pharma's revenue and profitability?
- Royalty Pharma generated $2.5B in trailing twelve-month revenue with net income of $815.0M, representing a net margin of 32.1%. These figures are based on the Q2 2026 filing.
- Who are Royalty Pharma's competitors?
- Royalty Pharma's key competitors include Ligand Pharmaceuticals Inc., Rigel Pharmaceuticals Inc. (New), BridgeBio Pharma, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Royalty Pharma partner with?
- Royalty Pharma's notable partners include Vertex Pharmaceuticals, GSK, Biogen, and others.
- What subsidiaries does Royalty Pharma have?
- Royalty Pharma's subsidiaries include Royalty Pharma Holdings Ltd, Royalty Pharma, LLC.
- Where is Royalty Pharma headquartered?
- Royalty Pharma is headquartered in United States of America and employs approximately 89 people. It has been publicly traded since 2020.
